The Epithalon protocol that arrives by email
Consider what the document is doing. It sets out a plan of action, it attaches a rationale, and it cites sources to show the plan is not arbitrary. That is a reasonable thing for a provider to produce, and a client is right to prefer it to a verbal instruction.
The difficulty is that the citations are carrying weight the reader cannot audit without doing an unusual amount of work. Most people see references and conclude that a literature exists. A literature does exist. What they cannot see from the reference list is that it comes overwhelmingly from one place.
One research group, and why that is the honest starting point
The published work on this compound is concentrated in the research programme of Khavinson and colleagues in St Petersburg, whose long running interest was pineal peptide preparations. This compound, a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, came out of that programme and is derived from a preparation called Epithalamin.
Saying so is not an accusation. Research groups specialise, and a group that spends decades on a topic will naturally produce most of the literature on it. Concentration is a fact about a field, not evidence of misconduct.
It is, however, a fact that changes how a finding should be read, and it is the single most important thing a consumer should understand before evaluating any document about this compound.
Independent replication is what turns a result into knowledge. Different people, different laboratories, different animals, different assumptions, different incentives, arriving at the same answer. When a result has been reproduced by groups with no stake in it, the ordinary sources of error, technique quirks, unnoticed bias in a protocol, selective emphasis, get filtered out. When it has not, those sources of error remain live possibilities. Not certainties. Possibilities that nobody has excluded.
So a finding reported once by one group and a finding reproduced by five independent groups are different kinds of claim, even if the sentences describing them read identically. A protocol that cites the first and presents it as the second has done something the reader cannot detect from the page.
Replication is the thing a single document cannot supply
This is where a plan handed to a client differs from a research protocol in a way that has nothing to do with how well it is written.
A registered research protocol is a public commitment made in advance: this outcome, in these people, against this comparison, for this long, reported whether or not it flatters the sponsor. It is filed, reviewed by an ethics committee, and departures from it must be declared. Its authority comes from the fact that it could have produced an unwelcome answer and would have had to say so.
A clinic plan makes no such commitment. It has no prespecified outcome, no comparison group, no independent review and no obligation to be published if things go badly. It can be revised at any moment without anyone being informed. That is not a criticism of the provider. It is a description of what kind of document it is.
For this compound the gap is wider than usual, because there is no registered interventional trial anywhere to sit at the other end of the comparison. There is no protocol to open, no prespecified endpoint to read, and no results entry to check a claim against.
Four documents, ranked by what they oblige anyone to do
Read the right hand column downward. The two documents that carry real obligations do not exist here. The two that do exist carry the fewest, and one of them is the one placed in your hands.
| Document | Written before the result is known | Independent oversight | Must be published either way | Exists for this compound |
|---|---|---|---|---|
| Registered trial protocol | Yes | Ethics committee | Yes | No |
| Approved product label | Follows completed review | Regulator | Yes | No, in any country |
| Published study from one group | Varies | Journal peer review | No | Yes, and concentrated in one programme |
| Clinic treatment plan | No | The provider | No | Yes, and this is what you are shown |
The citation that does the heaviest lifting
Certain phrases recur in these documents and each deserves a moment.
Clinically studied. Almost always true in the loosest sense and almost always doing more work than it should. Ask which organism, in which laboratory, and whether anyone outside that laboratory has reproduced it.
Shown to activate telomerase. This traces to the source programme's work, largely in cultured cells. Telomerase activity in a cell culture is a measurement in a dish. The distance between that and anything happening to a person over a lifetime is enormous, and it is bridged in the marketing by a sentence rather than by evidence.
Extends lifespan. Where this rests on anything, it rests on rodent work from the same programme. It has not been demonstrated in people, and presenting it as though it has is the most consequential thing anyone says about this compound.
Well tolerated. Tolerability reported by the group whose compound it is, in the absence of any independent safety collection, is the weakest form of this claim available.
None of these are outright falsehoods. Each is a real thing someone reported. The document's job, if it were honest, would be to say who reported it, in what organism, and whether anyone else has found the same.
What a plan would have to admit to be trustworthy
A short list, and none of it is difficult to write.
It would state that the compound holds no marketing authorisation in any country. It would state that the supporting literature is concentrated in one research programme and that independent replication is limited. It would separate findings in cultured cells from findings in rodents from anything reported in people, and label each. It would say that no registered interventional trial exists to consult. It would name the manufacturer of the actual vial and show what testing that batch received. And it would describe what the provider will do if something goes wrong.
A document that says all of that is not a weaker document. It is the only kind that tells you what you are deciding. A plan that reads as though the science is settled is either written by someone who has not checked, or written by someone who has.
What the document commits the practice to
There is a consumer question underneath all of this that has nothing to do with science, and it is often the more useful one.
Read the plan for obligations rather than for claims. Does it say what happens if you have a reaction, who you contact and how quickly they respond. Does it say what happens if you decide to stop partway through a paid course. Does it say who supplied the material and what testing that batch received. Does it commit the practice to anything at all, or does it only describe what you are expected to do.
Then read the terms attached to the sale, usually further down or on a separate page. That is where you will typically find language placing responsibility for use on the client, sometimes describing the material as research grade. Those clauses do real legal work. The rationale paragraph above them does none.
When a document is generous with claims and thin on obligations, that asymmetry is telling you how the practice understands the arrangement, whatever the tone of the consultation suggested. It is the cheapest check available and almost nobody performs it.